Skip to main content
Clinical Trials/NCT01256437
NCT01256437
Completed
Phase 2

Double Blind Placebo Controlled Trial, for Evaluating Preventive Therapy With Either Oint Threolone Versus Synthomycine Versus Aqua Cream, for EGFR'I Induced Acneiform Rash

Rabin Medical Center1 site in 1 country90 target enrollmentJanuary 2011

Overview

Phase
Phase 2
Intervention
Threolone ointment
Conditions
Acneiform Rash
Sponsor
Rabin Medical Center
Enrollment
90
Locations
1
Primary Endpoint
Number of patients developing grade 2 / above rash under preventative treatment with ointment threolone, compared to the other 2 treatment arms.
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The investigators hypothesized that topical anti-inflammatory treatment could counteract the inflammatory reaction induced by EGFR'Is.

Detailed Description

The investigators hypothesized that topical anti-inflammatory treatment could counteract the inflammatory reaction induced by EGFR'Is.

Registry
clinicaltrials.gov
Start Date
January 2011
End Date
March 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

iris amitay

Iris Amitay-Laish, MD

Rabin Medical Center

Eligibility Criteria

Inclusion Criteria

  • Patients who are planed to initiate treatment with either cetuximab , erlotinib, gefitinib or panitumumab.

Exclusion Criteria

  • Patients who received any facial topical treatment / systemic antibiotics or any anti-inflammatory drug during the 2 weeks prior to study initiation.
  • Known hypersensitivity to ointment Synthomycine or to Threolone.
  • Patients presented with cutaneous rash during the 2 weeks prior to study initiation

Arms & Interventions

ointment Threolone

Treatment with topical application of combined anti inflammatory and anti bacterial agent.

Intervention: Threolone ointment

ointment Threolone

Treatment with topical application of combined anti inflammatory and anti bacterial agent.

Intervention: ointment Synthomycine

ointment Threolone

Treatment with topical application of combined anti inflammatory and anti bacterial agent.

Intervention: Aqua cream

ointment Synthomycine

ointment once daily for 1 month

Intervention: ointment Synthomycine

ointment Synthomycine

ointment once daily for 1 month

Intervention: Aqua cream

Aqua cream

Intervention: Aqua cream

Outcomes

Primary Outcomes

Number of patients developing grade 2 / above rash under preventative treatment with ointment threolone, compared to the other 2 treatment arms.

Time Frame: 3 years

Secondary Outcomes

  • Number of patients developing a rash under preventative treatment with ointment threolone, compared to the other 2 treatment arms(3 years)

Study Sites (1)

Loading locations...

Similar Trials